Weekly Analysts’ Ratings Updates for Kestra Medical Technologies (KMTS)

Kestra Medical Technologies (NASDAQ: KMTS) has recently received a number of price target changes and ratings updates:

• 12/24/2025 – Kestra Medical Technologies had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/18/2025 – Kestra Medical Technologies had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/13/2025 – Kestra Medical Technologies had its price target raised by analysts at The Goldman Sachs Group, Inc. from $22.00 to $25.00. They now have a “neutral” rating on the stock.
• 12/12/2025 – Kestra Medical Technologies was given a new $30.00 price target on by analysts at Stifel Nicolaus.
• 12/12/2025 – Kestra Medical Technologies had its price target raised by analysts at Wells Fargo & Company from $27.00 to $28.00. They now have an “overweight” rating on the stock.
• 12/12/2025 – Kestra Medical Technologies had its price target raised by analysts at Piper Sandler from $27.00 to $30.00. They now have an “overweight” rating on the stock.
• 11/18/2025 – Kestra Medical Technologies is now covered by analysts at BTIG Research. They set a “buy” rating and a $32.00 price target on the stock.

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.